Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
Y Wang, W Zhang, Q Han, Y Liu, H Dai, Y Guo, J Bo… - Clinical …, 2014 - Elsevier
We conducted a trial testing a CD20-specific CAR coupled with CD137 and the CD3ζ moiety
in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL).
Seven patients were enrolled. One of the two patients with no bulky tumor obtained a 14-
month durable and ongoing complete remission by cell infusion only, and another attained a
6-month tumor regression. Four of five patients with bulky tumor burden were evaluable for
clinical efficacy, three of which attained 3-to 6-month tumor regression. Delayed toxicities …
in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL).
Seven patients were enrolled. One of the two patients with no bulky tumor obtained a 14-
month durable and ongoing complete remission by cell infusion only, and another attained a
6-month tumor regression. Four of five patients with bulky tumor burden were evaluable for
clinical efficacy, three of which attained 3-to 6-month tumor regression. Delayed toxicities …